4D Molecular Therapeutics completed enrollment in the phase 2 dose expansion stage of the PRISM clinical trial investigating 4D-150 for wet age-related macular degeneration, according to a press release.
“We believe, if approved, 4D-150’s differentiated clinical profile has the potential to greatly reduce the high treatment burden of current standard-of-care anti-VEGF therapies in wet AMD. This standard of care includes frequent injections, as often as monthly for certain patients,” David Kirn, MD, co-founder and CEO of 4DMT, told Healio. “4D-150 has the potential to